Suzhou Abogen Biosciences Co., Ltd.

Quick facts

Phase 2 pipeline

• ABO1020 · Oncology
  ABO1020 is a monoclonal antibody targeting PD-1.
• ABO1105 · Oncology
  ABO1105 is a small molecule that targets the PI3K/AKT/mTOR pathway.
• ABO1108 · Diabetes
  ABO1108 is a small molecule targeting the SGLT2 receptor.

Phase 1 pipeline

• ABO-CoV.617.2
• ABO1009-DP

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Suzhou Abogen Biosciences Co., Ltd. portfolio CI brief
• Suzhou Abogen Biosciences Co., Ltd. pipeline updates RSS